MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up

CONTEXT: Single-agent belamaf demonstrated deep and durable responses in the DREAMM-2 (NCT03525678) primary analysis (1) and long-term follow-up (2,3). Keratopathy (microcyst-like epithelial changes [MECs] observed on eye examination with/without symptoms) were managed through dose delays and reduct...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Lymphoma Myeloma Leuk
Autors principals: Cohen, Adam D, Lee, Hans C, Trudel, Suzanne, Abdallah, Al-Ola, Callander, Natalie, Libby, Edward, Karlin, Lionel, Lonial, Sagar, Womersley, Lynsey, Baron, January, Lewis, Eric, Nungesser, Katlyn, Gupta, Ira, Opalinska, Joanna
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Inc. 2020
Matèries:
Submitted Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7832238/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2152-2650(20)30949-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars